Fiche centre
Novartis Investigative Site
Essen — Germany
Essais liés12clinical trials
VilleEssenlocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07261631
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pelacarsen (TQJ230) | Accident vasculaire cérébral | Phase 3 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | ACTIVE_NOT_RECRUITING |
| 68Ga-NNS309 | Cancer | Phase 1 | NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | RECRUITING |
| AMO959 | Cancer | Phase 1/2 | NCT07226986 | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | RECRUITING |
| JSB462 | Cancer | Phase 2 | NCT07047118 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | ACTIVE_NOT_RECRUITING |
| Ribociclib | Cancer | Phase 3 | NCT05827081 | Adjuvant WIDER — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | RECRUITING |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06675864 | Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel | Lupus | Phase 2 | NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | ACTIVE_NOT_RECRUITING |
| AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis | SEP | À vérifier | NCT05344469 | AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis | RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04084314 | APOLLON — Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study | COMPLETED |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06617793 | An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Iptacopan | Myasthénie | Phase 3 | NCT06517758 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |